Christopher P. Wardell

7.5k total citations
69 papers, 2.3k citations indexed

About

Christopher P. Wardell is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Christopher P. Wardell has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 47 papers in Hematology and 18 papers in Cancer Research. Recurrent topics in Christopher P. Wardell's work include Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Genomics and Diagnostics (14 papers). Christopher P. Wardell is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Genomics and Diagnostics (14 papers). Christopher P. Wardell collaborates with scholars based in United Kingdom, United States and Italy. Christopher P. Wardell's co-authors include Gareth J. Morgan, Brian A. Walker, Faith E. Davies, Martin Kaiser, Laura Chiecchio, Kevin Boyd, Lorenzo Melchor, Fiona M. Ross, David C. Johnson and Annamaria Brioli and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Christopher P. Wardell

66 papers receiving 2.2k citations

Peers

Christopher P. Wardell
Florence Magrangeas France
Alessandra Di Bacco United States
Jan Krönke Germany
Amanda L. Christie United States
Leslie A. Brents United States
Luigia Lombardi Italy
Peter Grauman United States
Domenica Ronchetti Italy
Chang-Xin Shi United States
Markus Warmuth United States
Florence Magrangeas France
Christopher P. Wardell
Citations per year, relative to Christopher P. Wardell Christopher P. Wardell (= 1×) peers Florence Magrangeas

Countries citing papers authored by Christopher P. Wardell

Since Specialization
Citations

This map shows the geographic impact of Christopher P. Wardell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Wardell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Wardell more than expected).

Fields of papers citing papers by Christopher P. Wardell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Wardell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Wardell. The network helps show where Christopher P. Wardell may publish in the future.

Co-authorship network of co-authors of Christopher P. Wardell

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher P. Wardell. A scholar is included among the top collaborators of Christopher P. Wardell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher P. Wardell. Christopher P. Wardell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mann, Dan C., et al.. (2025). Evaluating Skellytour for Automated Skeleton Segmentation from Whole-Body CT Images. Radiology Artificial Intelligence. 7(2). e240050–e240050. 1 indexed citations
2.
Gökden, Murat, et al.. (2024). Long-read sequencing for brain tumors. Frontiers in Oncology. 14. 1395985–1395985. 1 indexed citations
3.
Peterson, Erich A., Matthew A. Steliga, Omar Atiq, et al.. (2023). An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics. Frontiers in Genetics. 13. 987175–987175.
4.
Reed, Megan R., Leena Maddukuri, Katrina Learned, et al.. (2021). A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells. 10(12). 3400–3400. 15 indexed citations
5.
Wardell, Christopher P., et al.. (2021). Genomic and Transcriptomic Profiling of Brain Metastases. Cancers. 13(22). 5598–5598. 3 indexed citations
6.
Wardell, Christopher P., Cody Ashby, & Michael Bauer. (2021). FiNGS: high quality somatic mutations using filters for next generation sequencing. BMC Bioinformatics. 22(1). 77–77. 6 indexed citations
7.
Śmiech, Magdalena, et al.. (2020). Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes. 11(11). 1342–1342. 103 indexed citations
8.
Bauer, Michael, Cody Ashby, Christopher P. Wardell, et al.. (2020). Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 106(3). 736–745. 22 indexed citations
9.
10.
Nakagawa, Hidewaki, Christopher P. Wardell, Mayuko Furuta, Hiroaki Taniguchi, & Akihiro Fujimoto. (2015). Cancer whole-genome sequencing: present and future. Oncogene. 34(49). 5943–5950. 69 indexed citations
11.
Mirabella, Fabio, Alexander Murison, Lauren I. Aronson, et al.. (2014). A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex. PLoS ONE. 9(6). e99493–e99493. 7 indexed citations
12.
Walker, Brian A., Christopher P. Wardell, David C. Johnson, et al.. (2013). Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 121(17). 3413–3419. 100 indexed citations
13.
Bøgsted, Martin, Anders Ellern Bilgrau, Christopher P. Wardell, et al.. (2013). Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. PLoS ONE. 8(12). e83252–e83252. 9 indexed citations
14.
Walker, Brian A., Christopher P. Wardell, Lorenzo Melchor, et al.. (2013). Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 28(2). 384–390. 204 indexed citations
15.
Mirabella, Fabio, Pingping Wu, Christopher P. Wardell, et al.. (2013). MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer Journal. 3(5). e114–e114. 35 indexed citations
16.
Kozarewa, Iwanka, Juan Manuel Rosa-Rosa, Christopher P. Wardell, et al.. (2012). A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA. PLoS ONE. 7(3). e32617–e32617. 18 indexed citations
17.
Boyd, Kevin, Fiona M. Ross, Laura Chiecchio, et al.. (2011). Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1703–1707. 33 indexed citations
18.
Boyd, Kevin, Fiona M. Ross, Brian A. Walker, et al.. (2011). Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research. 17(24). 7776–7784. 131 indexed citations
19.
Boyd, Kevin, Fiona M. Ross, William Tapper, et al.. (2011). The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy. Genes Chromosomes and Cancer. 50(10). 765–774. 50 indexed citations
20.
Boyd, Kevin, F. M. Ross, Laura Chiecchio, et al.. (2011). A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 26(2). 349–355. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Magrangeas Breakdown of academic impact, for papers by Alessandra Di Bacco Breakdown of academic impact, for papers by Jan Krönke Breakdown of academic impact, for papers by Amanda L. Christie Breakdown of academic impact, for papers by Leslie A. Brents Breakdown of academic impact, for papers by Luigia Lombardi Breakdown of academic impact, for papers by Peter Grauman Breakdown of academic impact, for papers by Domenica Ronchetti Breakdown of academic impact, for papers by Chang-Xin Shi Breakdown of academic impact, for papers by Markus Warmuth
Rankless by CCL
2026